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Abstract
Circulating malignant CD19 B cells have been implicated in the pathogenesis and relapse of multiple myeloma (MM).
This study investigated the therapeutic applicability of using long-circulating liposome-encapsulated doxorubicin (DXR)
targeted against the internalizing CD19 antigens present on human MM cells. In vitro binding studies using the CD19 MM
cell line ARH77 demonstrated that CD19-directed immunoliposomes (SIL[anti-CD19]) specifically attached to these cells.
Formulations of immunoliposomal doxorubicin (DXR-SIL[anti-CD19]) showed a higher association with, and higher
cytotoxicity against, ARH77 cells than did non-targeted liposomal doxorubicin (DXR-SL) or isotype-matched controls
(DXR-NSIL[IgG2a]). By using the pH-sensitive fluorophore, 1-hydroxypyrene-3,6,8-trisulfonic acid, binding of SIL[anti-
CD19] to CD19 antigens was shown to trigger receptor-mediated internalization of the antibody^antigen complexes into
endosomes. Targeting of SIL[anti-CD19] to CD19 B cells was also demonstrated in a heterogeneous mixture of peripheral
blood mononuclear cells (PBMC) from MM patients. A decrease in cellular DNA (which is an indicator of apoptosis) caused
by the cytotoxicity of DXR-SIL[anti-CD19] to myeloma PBMC was determined by using flow cytometry. While PBMC
treatment with free DXR resulted in non-specific cytotoxicity to both B and T cells, DXR-SL were only minimally cytotoxic
to either. In contrast, DXR-SIL[anti-CD19] were selectively cytotoxic for B cells in PBMC, indicating that this treatment
may be effective in eliminating circulating malignant B cells in MM patients. ß 2000 Elsevier Science B.V. All rights
reserved.
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1. Introduction
Multiple myeloma (MM) is a malignancy of the
immune system; it is identi¢ed clinically by the pres-
ence of terminally di¡erentiated neoplastic plasma
cells in the bone marrow [1]. Although most patients
with MM initially respond to conventional chemo-
therapy, nearly all relapse within 1^2 years. Both
aggressive combination chemotherapy and high
dose chemotherapy followed by a bone marrow
transplant increase the relapse-free interval; however,
in most cases the disease eventually recurs and is
refractory to further treatment [1^3].
Recent reports on MM have described a circulat-
ing population of monoclonal CD19 B cells [4^6]
that exhibit extensive DNA aneuploidy [7] and dis-
play traits consistent with the invasive progenitors of
plasma cells [8^11]. These monoclonal cells also ex-
press a functional p-glycoprotein plasma membrane
transporter (P-gp) [12,13] that has been implicated in
drug resistance and is correlated with chemothera-
peutic failure [14,15]. Current therapies for MM
have focussed on eradicating the malignant plasma
cells in bone marrow, but such therapies have been
largely unsuccessful in preventing relapse [1,3]. It has
been suggested that, in MM, chemotherapy does not
eliminate the malignant B cells in the blood and that
relapse occurs because these cells repopulate the
bone marrow [4,6^8,14].
The CD19 receptors present on the circulating
monoclonal B cells seen in MM are known to be
internalizing; these receptors have been implicated
in a number of signalling functions [16^19]. Further,
the binding of monoclonal antibody (mAb) to these
receptors has been shown to trigger a cascade of
intracellular messages that commit cells to di¡eren-
tiate and/or undergo cell-cycle arrest or apoptosis
[16,20]. Thus, a possible approach to the eradication
of malignant B cells in the blood of MM patients
may involve the use of immunoliposomal anticancer
drugs targeted against the CD19 antigen, or other
internalizing antigens, on B cells. This receptor has
already been a target for a number of antibody-based
therapies; pre-clinical and clinical trials are currently
underway to determine the e¡ect of several treatment
variations (free mAb, radiolabelled mAbs or immu-
notoxins [17,21^26]) on a variety of B cell cancers. It
is possible that coupling of mAbs, such as anti-
CD19, to long-circulating liposomal drugs will have
advantages beyond those realized by speci¢cally tar-
geting receptors on the malignant cells. For instance,
higher drug to antibody ratios can be achieved by
using liposomal drug delivery systems; in addition,
attaching the mAb at the terminus of poly(ethylene-
glycol) (PEG) results in longer circulation half-lives
for the targeted liposomes, which may, in turn, in-
crease the binding and uptake of liposomal drugs by
circulating malignant cells [27^29].
Immunoliposomal therapy has been shown to be
e¡ective in models of solid tumors in animals [29^31]
and in the treatment of a murine xenograft model of
human B cell lymphoma [32]; however, its applicabil-
ity to treatment of MM remains uncharacterized. We
hypothesize that in MM, treatment with immunoli-
posomes will selectively eradicate the circulating ma-
lignant CD19 B cell population while causing min-
imal toxicities to normal tissues (including T cells,
thereby preserving the immune responses mediated
by them). Besides eliminating these cells (which, as
previously mentioned, may prevent relapse and im-
prove patient survival by keeping these cells from
reaching bone marrow and extra-skeletal tissues), im-
munoliposomal therapy may initiate endocytosis trig-
gered by the internalizing CD19 receptor, thus by-
passing membrane drug transporter(s) and allowing
delivery of high levels of the cytotoxic agent to oth-
erwise resistant cells [13,14].
To test our hypothesis, we evaluated the targeting
and cytotoxicity of anti-CD19 immunoliposomal
doxorubicin (DXR) to both monoclonal B cell lym-
phocytes from the blood of patients with MM and to
a human MM cell line (ARH77). Two formulations
of DXR-sterically stabilized immunoliposomes
(DXR-SIL) (prepared with phospholipids (PLs) hav-
ing di¡erent phase transition temperatures) were
compared with respect to their binding, intracellular
tra⁄cking and cytotoxicity to CD19 myeloma cells.
2. Materials and methods
2.1. Chemicals
PEG, molecular weight 2000, covalently linked to
distearoyl phosphatidylethanolamine (PEG2000-
DSPE), hydrazide-derivatized PEG-DSPE (Hz-
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PEG-DSPE), hydrogenated soy phosphatidylcholine
(HSPC) and partially hydrogenated egg phosphati-
dylcholine with an iodine number 40 (PC40) were
generous gifts from SEQUUS Pharmaceuticals
(Menlo Park, CA, USA) [33^35]. Cholesterol
(CHOL) and 12-[N-(nitrobenz-2-oxa-1,3-diazol-4-
yl)amino]dodecanoyl phosphatidylethanolamine
(NBD-PE) were purchased from Avanti Polar Lipids
(Alabaster, AL, USA). 1-Hydroxypyrene-3,6,8-trisul-
fonic acid (HPTS) was obtained from Molecular
Probes (Eugene, OR, USA). Sephadex G50, Sephar-
ose CL-4B and Ficoll-Paque were obtained from
Amersham Pharmacia Biotech (Uppsala, Sweden).
N-Acetyl-methionine (NAM), sodium periodate,
4,6-diamidino-2-phenylindole (DAPI) and 3-[4,5-di-
methylthiazol-2-yl]-2,5-diphenyltetrazolium bromide
(MTT) were purchased from Sigma (St. Louis,
MO, USA). DXR (adriamycin RDF) was obtained
from Adria Laboratories (Mississauga, Ont., Cana-
da). RPMI 1640 media without phenol red, penicil-
lin-streptomycin and fetal bovine serum (FBS) were
purchased from Gibco BRL (Burlington, Ont., Can-
ada). Cholesteryl-[1,2-3H-(N)]-hexadecyl ether ([3H]-
CHE), 1.48^2.22 TBq/mmol, was purchased from
New England Nuclear (Mississauga, Ont., Canada).
Scintillation £uor/aqueous counting scintillant (ACS)
was purchased from Amersham Canada (Oakville,
Ont., Canada). Nucleopore polycarbonate ¢ltration
membranes (pore sizes: 0.4, 0.2, 0.1 and 0.08 Wm)
were obtained from Corning Costar (Kennebunk,
ME, USA). All other chemicals, which came from
various sources, were of analytical grade purity.
2.2. Antibodies, human cells and cell lines
Murine mAb anti-CD19 (IgG2a, immunoglobulin
2a) (from FMC63 murine CD19 hybridoma) and iso-
type-matched control IgG2a (IAG.11) were obtained
from Dr. H. Zola (Child Health Research Institute,
Adelaide, Australia) [18,36]. The MAbs anti-CD19
(IgG1), anti-CD22 (IgG1) and the isotype-matched
control (IgG1) were a generous gift from Dr. E. Vi-
tetta (University of Texas Southwestern Medical
Centre, Dallas, TX, USA). Anti-CD45-phycoerythrin
(anti-CD45-PhE) was mAb 17G10 from Dr. J. Wil-
kins (University of Manitoba, Winnipeg, Man., Can-
ada). Mouse monoclonal antibodies speci¢c for hu-
man leukocyte di¡erentiation antigens CD4, CD8
and CD20 were either prepared in one of our labo-
ratories or purchased from Coulter (Hialeah, FL,
USA) or Becton Dickinson (San Jose, CA, USA).
The concentrations of all laboratory mAbs were de-
termined by using spectrophotometry (V= 280 nm)
and BioRad protein assays; their purity was assessed
by sodium dodecyl sulfate^polyacrylamide gel elec-
trophoresis. The reactivities of mAb were checked
prior to use by indirect immuno£uorescence using
£uorescein isothiocyanate (FITC)-labelled goat anti-
mouse Ab and £ow cytometry (Becton Dickinson,
San Jose, CA, USA) against appropriate cell lines,
followed by comparison with appropriate FITC or
PhE-conjugated isotype-matched controls.
Human peripheral blood mononuclear cells
(PBMC) from MM patients were obtained after in-
formed consent. Patients in this study were either
newly diagnosed with the disease or were already
undergoing chemotherapy. PBMC were isolated via
Ficoll-Paque density gradient centrifugation (Phar-
macia). Brie£y, blood obtained from MM patients
was diluted 1:1 with phosphate-bu¡ered saline
(PBS) and carefully layered on 20 ml Ficoll-Paque
in a 50 ml polypropylene tube. The tubes were cen-
trifuged for 25 min at 1800 rpm. After centrifugation
and prior to experimental use, PBMC were collected
from the interface, washed with PBS and re-sus-
pended at a density of 1U107 cells/ml in RPMI
1640 media containing 10% FBS. Their viability
was then assessed by staining with eosin, then using
a haemocytometer to count the percentage of dead
(i.e. stained) cells.
The human MM cell line ARH77 (ATCC
CRL1621) was obtained from the American Type
Culture Collection (Rockville, MD, USA). ARH77
cells were grown as suspension cultures in RPMI
1640 with no phenol red, supplemented with 10%
heat-inactivated FBS and 1% penicillin-streptomycin
(10 000 unit/ml penicillin G and 10 000 Wg/ml strep-
tomycin sulfate). Cells were maintained at 37‡C in a
90% humidi¢ed incubator containing 5% CO2. All
experiments were performed on mycoplasma-free
cell lines. For in vitro experiments, only cells in the
exponential phase of growth were used.
2.3. Immunophenotyping of MM cells
Flow cytometry was used to phenotype the human
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MM cell line (ARH77) and peripheral blood mono-
nuclear cells (PBMC) from MM patients with anti-
bodies against lymphocyte di¡erentiation antigens
(see Table 1). These antibodies were either puri¢ed
mAbs or were conjugated to FITC or PhE. Brie£y,
ARH77 cells (1U106 cells) were incubated in dark-
ness with 10 Wg mAb/106 ARH cells at 4‡C for 30 min
in a total volume adjusted to 50 Wl with PBS. After
incubation, cells were washed three times with immu-
no£uorescence bu¡er (IF bu¡er: PBS-containing 1%
FBS and 0.1% sodium azide) and analyzed by £ow
cytometry. For indirect staining, subsequent to addi-
tion of primary Ab and washing, cells were incubated
with 50 Wl of 1:20 dilution of goat anti-mouse-FITC
IgG (Sigma) in PBS at 4‡C for 30 min. In some
cases, cells were ¢xed with 1% formalin in PBS.
Cell-associated £uorescence was analyzed on Becton
Dickinson FACScan using LYSIS II software (Bec-
ton Dickinson, San Jose, CA, USA). FITC and PhE
£uorescent markers were excited with an argon laser
(488 nm) and the emitted £uorescence was detected
through 530 (FITC) or 560 nm (PhE) band pass
¢lters, respectively.
2.4. Preparation of liposomes
Liposomes were composed of either
HSPC:CHOL:mPEG2000-DSPE (2:1:0.1 molar ra-
tio) or PC40:CHOL:Hz-PEG2000-DSPE (2:1:0.1 mo-
lar ratio). In some preparations, [3H]CHE was added
as a non-exchanged, non-metabolized lipid tracer
[37,38]. Fluorescent-labelled liposomes were prepared
by incorporating NBD-PE (1 mol%) into the lipid
mixture. Dried lipid ¢lms were hydrated using a so-
lution of 25 mM HEPES (pH 7.4) and 140 mM NaCl
or 155 mM ammonium sulfate pH 5.5 (for DXR
loading), then sequentially extruded (Lipex Biomem-
branes Extruder, Vancouver, BC, Canada) through
polycarbonate ¢lters of varying pore sizes (0.08^
0.4 Wm) to produce vesicles 95^110 nm in diameter
[39]. Liposome size was characterized on a Brook-
haven BI90 particle sizer (Brookhaven Instruments,
Holtsville, NY, USA). PL concentrations were deter-
mined by using either the speci¢c activity counts of
[3H]CHE tracer or the Bartlett colorimetric assay
[40]. The number of liposomes in the liposome dis-
persion was estimated at 7.7U1012 liposomes/Wmol
PL [32,41].
DXR was remote-loaded via an ammonium sulfate
gradient method previously described [32,42]. Lipo-
some-encapsulated DXR was separated from free
DXR on a Sephadex G-50 column equilibrated
with 123 mM sodium citrate (pH 5.5). The concen-
tration of the liposome-entrapped DXR was 150 Wg
DXR/Wmol PL (0.26 Wmol DXR/Wmol PL, as deter-
mined by spectrophotometry (V= 480 nm in metha-
nol).
By using a previously described hydrazide coupling
method [32,43], antibodies were coupled to the ter-
minus of pre-formed liposomes that contained the
coupling lipid Hz-PEG-DSPE. From the speci¢c ac-
tivity of the 125I-anti-CD19 label incorporated during
coupling, we calculated the concentration of anti-
CD19 on liposomes to be 50 Wg anti-CD19/Wmol
PL. On the basis of a concentration of 7.7U1012
liposomes/Wmol PL, we calculated that there were
approximately 25 antibodies/liposome [32].
2.5. Cell uptake experiments
ARH77 cells were plated in 48-well tissue culture
plates at 1U106 cells/100 Wl RPMI 1640 supple-
Table 1
Immunophenotyping of ARH cells or PBMC from MM pa-
tients using £ow cytometry
Leukocyte di¡erentiation antigens Relative expression on
cellsa
ARH cells PBMC
CD4 (T cell) 3 ++1/2





IgG2a (control) 3 3
The human MM cell line ARH77, or PBMC from MM pa-
tients, were incubated with appropriate mAbs (10 Wg mAb/106
cells) at 4‡C for 30 min. Cell surface markers were evaluated
by immunostaining with speci¢c Abs, by either direct or indi-
rect immuno£uorescent staining methods (see Section 2). Cells
were washed with IF bu¡er and cell-associated £uorescence was
analyzed on a Becton Dickinson £ow cytometer.
aThe reactivities of mAbs with cells were scored relative to their
mean £uorescence intensity (MFI) of staining using £ow cyto-
metry: ++++ MFI 104 (very high); +++ MFI 103 (high); ++
MFI 102 (moderate) ; + MFI 101 (low); +/3 ;MFI 100:5ÿ1 (very
low); 3 MFI6 100:5 (negative). Unstained control cells were set
at 6 100:5 MFI.
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mented with 10% FBS. Various formulations of 3H-
CHE-labelled liposomes, with or without coupled
anti-CD19, were added to each well (200 Wl total
volume, 50^1600 nmol/ml) and maintained at 37‡C
with 90% humidity and 5% CO2. After 1 h incuba-
tion, the cells were washed three times with cold PBS
(pH 7.4) and cell-associated liposomes were deter-
mined from the initial speci¢c activity of the 3H-
CHE-liposomes.
In some experiments, the association of cells with
immunoliposomes labelled with 1 mol% of the £uo-
rescent lipid marker NBD-PE was determined by
£ow cytometry. Various formulations of NBD-PE-
labelled liposomes (400 nmol PL/ml) were incubated
(for 1 or 24 h at 37‡C) with 1U106 ARH77 cells. In
competition experiments, targeted NBD-SIL[anti-
CD19] liposomes were incubated with a 30-fold ex-
cess of free anti-CD19 (6.4U1034 Wmol anti-CD19).
Cells were washed three times with IF bu¡er and
¢xed in 1% formalin prior to analysis on the £ow
cytometer. Cell debris was excluded by appropriate
gating on ‘forward’ versus ‘side angle’ scatter pro-
¢les. Data were recorded from 5000^20 000 events
and later analyzed using the LYSIS II software pro-
gram (Becton Dickinson, San Jose, CA, USA). For
two-color immuno£uorescence experiments with
PBMC from MM patients, cells were labelled with,
in addition to £uorescent liposomes, either anti-
CD20-PhE (B cell marker) or a combination of
anti-CD4-PhE and anti-CD8-PhE (T cell markers),
which allowed us to identify the individual lympho-
cyte populations.
To determine the association of DXR with
ARH77 cells using £ow cytometry, cells were incu-
bated with either free DXR or various liposomal
DXR formulations at concentrations of drug ranging
from 0.1 to 100 Wg/ml for 1, 4 or 24 h at 37‡C. Cells
were then washed with cold IF bu¡er and immedi-
ately run on a Becton Dickinson FACScan (Becton
Dickinson, San Jose, CA, USA). Cell-associated
DXR was excited with an argon laser (488 nm) and
the £uorescence was detected at 560 nm. Files were
collected of 20 000 ungated events and analyzed with
the LYSIS II software program.
The internalization of liposomes by ARH77 cells
was studied using the encapsulated pH-sensitive £uo-
rescent probe HPTS (pyranine); this technique has
been described elsewhere [44,45]. Cells (1U106/well)
were incubated, at 37‡C for either 1 or 24 h, with
various formulations of HPTS-liposomes at a ¢nal
PL concentration of 400 nmol/ml. They were then
washed three times with PBS; the cell-associated
£uorescence spectrum was then determined by scan-
ning the excitation spectra from 320 to 500 nm, with
the emission wavelength ¢xed at 510 nm. From the
excitation spectra of the HPTS molecules, the pH of
the liposomal environment upon interaction with
ARH77 cells was determined from a previously pre-
pared standard curve of the free HPTS ranging from
pH 5 to 9.
The intracellular distribution of liposomes was de-
termined using confocal laser scanning microscopy.
PBMC from MM patients (1U106 cells/well) were
incubated with either free DXR or liposomal formu-
lations of DXR (20 Wg/ml in a total volume of 500 Wl
media) for 1 h at 37‡C. After incubation, cells were
washed with cold PBS and stained for 30 min with
anti-CD19-FITC. Cells were allowed to adhere onto
poly-L-lysine-coated slides prior to mounting with
PermaFluor (Lipshaw Immunon, Pittsburgh, PA,
USA). Cells were visualized on a Leitz Aristoplan
Fluorescence Microscope illuminated by a 100 W
HBO mercury burner for direct observation and an
argon^krypton laser with major emissions at 488,
568 and 647 nm for scanning observations. Cells
were optically sectioned over a random ¢eld of cells.
Images (512U512 pixel) were stored on optical disks
for further analyses using Leica Lasertechnick (Hei-
delberg, Germany) software. All instrumental param-
eters pertaining to £uorescence illumination, detec-
tion and image analyses were held constant as
follows: 100/1.32 oil-immersion objective lens, pin-
hole 100, o¡-sets 329/330, KP590 short-pass excita-
tion ¢lter, neutral beam-splitter, barrier long-pass ¢l-
ter OG 590, and a photomultiplier gain of 790 V.
2.6. Cytotoxicity experiments
The MTT proliferation assay was used to compare
the cytotoxicities of various liposomal formulations
to CD19+ARH77 cells [46]. These formulations in-
cluded free DXR, DXR-HSPC-SL, DXR-HSPC-SI-
L[anti-CD19] and DXR-HSPC-NSIL[IgG2a] with or
without free mAb anti-CD19 or isotype-matched
control IgG2a. In some experiments, PC40 was sub-
stituted for HSPC. The IC50 (inhibitory concentra-
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tion for 50% cell growth) was determined as de-
scribed in a previous publication [32].
The cytotoxicity of DXR or liposomal DXR to the
B lymphocyte populations in PBMC samples from
myeloma patients was evaluated using DAPI binding
to quantify apoptotic cells [47,48]. Treatment groups
were assigned to each patient sample, depending
upon the number of PBMC isolated from individual
patients. PBMC (2U106 cells/well) were incubated
with either DXR or di¡erent formulations of liposo-
mal DXR for 24 h at 37‡C. After incubation, cells
were washed, re-plated and incubated for an addi-
tional 48 h at 37‡C in RPMI 1640 media plus 10%
FBS. At the end of the assay, cell viability was as-
sessed using eosin dye exclusion. Myeloma PBMC
were stained with the appropriate mAbs for detecting
B (anti-CD19-FITC) or T (anti-CD4,8-PhE) cells, as
well as with DAPI to detect DNA content. DAPI
staining was done on ethanol-permeabilized (70%
ethanol at 4‡C) and RNase-treated cells at a ¢nal
DAPI concentration of 1.5 Wg/ml. Chicken red blood
cells (Crbc), which have one-third the cellular DNA
content of human red blood cells, were used as an
internal standard. The positions of the B and T cell
diploid peaks were set relative to the Crbc peak.
Samples were immediately run on the Elite £ow cy-
tometer (Coulter, Hialeah, FL, USA), with both
FITC and PhE excited at 488 nm by the argon laser
and simultaneous UV excitation of DAPI at 353 nm
by the water-cooled laser. Files of 10 000^40 000
events were collected and these were ungated to pre-
vent the exclusion of any drug-induced apoptotic
cells. Files were analyzed by listmode using the
ELITE software (Coulter). Electronic gates were set
for B cells or T cells to evaluate individual DAPI
pro¢les against appropriate FITC or PhE isotype-
matched mAb controls. B cells consisted of all
CD19-positive, CD4,8-negative cells. Cell doublets
were excluded during analyses by appropriate gating
on DAPI intensity versus DAPI peak. The histogram
pro¢les of DAPI staining of T cells were ¢rst ana-
lyzed to identify the position of the diploid peak (2N
number of chromosomes) relative to the Crbc inter-
nal standard. In order to include untreated cells with-
in this marker, the diploid peak marker was set at
twice the standard deviation (i.e. 95% con¢dence in-
terval). Relative to this diploid peak (2N), appropri-
ate statistical markers were selected to identify cells
having a hypodiploid DNA content (at least 2S.D.
lower than that of autologous diploid T cells), which
is indicative of apoptosis.
2.7. Statistical analyses
All linear regression analyses were performed us-
ing Quattro Pro 4.0 (Borland, Scotts Valley, CA,
USA). Unless otherwise stated, the two-tailed Stu-
dent’s t-test (INSTAT, GraphPAD software, version
1.11a) was used to measure statistical signi¢cance,
assuming equal variances with 95% con¢dence inter-
vals. Using one-way analysis of variance, multiple
comparisons of various groups in cytotoxic assays
were evaluated, again on INSTAT. Post-tests to
compare the various treatment means were per-
formed using Bonferroni’s tests. Data were consid-
ered statistically signi¢cant at P6 0.05. Data are re-
ported as mean þ standard deviation (S.D.).
3. Results
3.1. Cell immunophenotyping
The expression of selected leukocyte di¡erentiation
antigens on ARH77 and BPBMC cells (containing
both B and T cells) from MM patients was compared
with that of controls stained with their appropriate
isotype-matched IgG1 or IgG2a antibodies conju-
gated to FITC or PhE (Table 1). Anti-CD19 bound
to ARH77 cells and to PBMC cells from MM pa-
tients, presumably to a population of B cells (Table
1). Antibodies to CD4 and CD8 did not bind to B
cells, but did bind to PBMC, presumably to the T
cell population in patients’ blood. B cell mAbs did
not cross-react with the T cell lymphoma cell line H9
(not shown). Using £ow cytometry after staining
with anti CD19-FITC, the number of CD19 recep-
tors on ARH77 cells was estimated by comparing the
MFI of ARH77 cells with that of the human B lym-
phoma cell line (Namalwa), which expresses approx-
imately 40 000 CD19 receptors per cell. [18,49,50].
From the binding curves of free anti-CD19-FITC
to ARH77 cells (at saturation binding), the relative
density of CD19 receptors on ARH77 cells was esti-
mated at approximately 3000 sites per cell (not
shown).
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3.2. Cell uptake experiments
Binding experiments were conducted using
3H[CHE]-labelled liposomes (Fig. 1). SIL[anti-
CD19] showed a two- to three-fold higher binding
to ARH77 cells than to either non-targeted SL (steri-
cally stabilized liposomes) or isotype-matched con-
trol liposomes NSIL[IgG2a] (Fig. 1). At maximum
binding there were approximately 6.9U1034 or
2.1U1034 Wmol PL binding sites/106 cells for SIL[an-
ti-CD19] and SL, respectively. The dissociation con-
stant KD for the SIL[anti-CD19] was estimated at
220 WM, which was two-fold lower that for SL.
Using £ow cytometry, similar experiments were
performed using 1-h incubations of £uorescent
NBD-PE-labelled HSPC-CHOL liposomes (Fig. 2).
ARH77 cells showed greater binding of free anti-
CD19-FITC than did irrelevant IgG2a-FITC or un-
treated cells (Fig. 2a). Increased binding was not ob-
served for either SL or NSIL[IgG2a] to ARH77 cells
(Fig. 2b), but SIL[anti-CD19] binding was twice that
of non-targeted liposomes (Fig. 2b versus c). Com-
petition with excess free anti-CD19 was able to in-
hibit the binding of SIL[anti-CD19] with ARH77
cells, indicating binding speci¢city of the immunoli-
posomes (Fig. 2c). Similar two-fold increases in bind-
ing were observed at 1 h for a more £uid formulation
composed of PC40:CHOL (not shown). With 24-h
incubations, non-speci¢c association of non-targeted
liposomes (SL) to ARH77 cells increased approxi-
mately ¢ve-fold over that of the 1-h incubations,
but the binding of immunoliposomes was still two-
fold higher than the binding of non-targeted lipo-
somes (not shown).
ARH77 cells (1U106 cells/well) were incubated
(for 1 and 24 h at 37‡C) with either free DXR or
liposomal DXR at a DXR concentration of 20 Wg
DXR/ml. Relative cell-associated DXR was analyzed
using £ow cytometry (Fig. 3). Free DXR rapidly
Fig. 2. In vitro binding of £uorescent NBD-labelled liposomes
to ARH77 cells using £ow cytometry. NBD-labelled liposomes
105 nm in diameter (0.1 mol%) were composed of either
HSPC:CHOL:Hz-PEG-2000-DSPE (2:1:0.1 molar ratio) þ mAb
anti-CD19 or isotype-matched control IgG2a. ARH77 cells
were incubated with various formulations of liposomes
(400 nmol PL/ml) for 1 or 24 h at 37‡C. Excitation was at
480 nm (argon laser) and emission at 510 nm. Histogram over-
lays illustrate: (a) unstained cells (dotted line) or cells treated
with either irrelevant antibody IgG2a-FITC (dashed line) or
anti-CD19-FITC (bold line) ; (b) SL (dotted line) or NSIL-
[IgG2a] (bold line) at 1 h; (c) free anti-CD19+SIL[anti-CD19]
(dashed line) and SIL[anti-CD19] (bold line) at 1 h.
Fig. 1. Binding of [3H]CHE-labelled liposomes by ARH77 cells
as a function of liposome concentration. Liposomes 104 nm in
diameter were composed of either HSPC:CHOL:PEG2000-
DSPE, 2:1:0.1 þ mAb anti-CD19 or isotype-matched control
mAb IgG2a attached via a hydrazone bond at the PEG termi-
nus, at approximately 50 Wg mAb/Wmol PL. SL (E), SIL[anti-
CD19] (F) or NSIL[IgG2a] (O) were incubated with 106
ARH77 cells for 1 h at 37‡C. Data are expressed as nmol
PL þ S.D. per 106 cells (n = 3).
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accumulated in ARH77 cells within 1 h at 37‡C (Fig.
3b). The two targeted formulations (Fig. 3e,f) had
three-fold higher DXR levels at 1 h than the non-
targeted formulations (Fig. 3c,d). The cellular DXR
levels for the two targeted formulations were 5^8-
fold lower than that seen for free DXR (Fig. 3e,f,
versus b). At 24 h, DXR-HSPC-SIL[anti-CD19] had
DXR levels twice that of the non-targeted formula-
tions (Fig. 3e versus c,d). As expected, higher cellular
DXR levels were seen at 24 h for the leakier PC40-
containing targeted formulation relative to the rela-
tively non-leaky HSPC targeted formulation (1.5-
fold increase, Fig. 3e versus f).
To determine whether receptor-mediated internal-
ization of immunoliposomes is triggered by binding
of SIL[anti-CD19] liposomes to ARH77 cells, we
used a previously described spectro£uorimetric assay
[44,45]. Incubation of ARH77 cells at 37‡C for 1 h
with HSPC-SIL[anti-CD19] or PC40-SIL[anti-
CD19], both of which contained entrapped HPTS,
was associated with a drop in pH from pH 7.3 to
pH 6.5^6.6 (P6 0.01) (Fig. 4). A further drop in pH
occurred after 24-h incubations (Fig. 4C). Both for-
mulations of SIL[anti-CD19] appeared to internalize
at similar rates and to similar extents (Fig. 4)
(Ps 0.05). No pH change was observed when SIL-
[anti-CD19] were incubated with the control CD193
T cell line H9 (not shown). The internalization of
liposomal HPTS into ARH77 cells was inhibited at
4‡C or by 0.1% sodium azide (Fig. 4A and D), sug-
gesting a metabolic requirement for the acidi¢cation
of liposomal HPTS. No pH drop was observed for
either the non-targeted SL or the isotype-matched
control liposomes (NSIL[IgG2a]) (Ps 0.05), a ¢nd-
ing consistent with non-speci¢c absorption of lipo-
somes at the cell surface (Fig. 4).
3.3. Cytotoxicity experiments
As shown in Table 2, after 1 h incubation DXR-
HSPC-SIL[anti-CD19] or DXR-PC40-SIL[anti-
CD19] were more cytotoxic to ARH77 cells than
were their non-targeted counterparts, DXR-HSPC-
SL (P6 0.01), DXR-PC40-SL (P6 0.01) or DXR-
Fig. 3. Flow cytometric analyses of the association of free DXR and liposomal DXR with ARH77 cells. ARH77 cells (1U106 cells/
well) were incubated with either free DXR or various formulations of liposomes 108 nm in diameter at a ¢nal DXR concentration of
20 Wg/ml for either 1 h (dotted line) or 24 h (bold line) at 37‡C. Cells were washed and cell-associated DXR was evaluated using £ow
cytometry. Histogram overlays illustrate: (a) untreated cells ; (b) free DXR; (c) DXR-SL (no mAb); (d) DXR-NSIL[IgG2a]; (e) DXR-
HSPC-SIL[anti-CD19] ; and (f) DXR-PC40-SIL[anti-CD19].
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HSPC-NSIL[IgG2a] (P6 0.001). The IC50 of the
leakier formulation DXR-PC40-SIL[anti-CD19],
which was lower than that of DXR-HSPC-SIL[an-
ti-CD19] (P6 0.001), was equivalent to the cytotox-
icity of free DXR (Ps 0.05) after 1 h incubation at
37‡C (Table 2). At 24 h, the IC50s of all DXR-for-
mulations were reduced (P6 0.01) (Table 2). At 24 h,
DXR-PC40-SIL[anti-CD19] were more cytotoxic
than free DXR (P6 0.001), DXR-HSPC-SIL[anti-
CD19] (P6 0.001) or non-targeted DXR-PC40-SL
(P6 0.05). HSPC-SIL[anti-CD19] were 17^27 times
more cytotoxic than either DXR-HSPC-SL or
DXR-HSPC-NSIL[IgG2a] at 1 h and 8^11 times
more cytotoxic at 24 h (Table 2), suggesting that,
at later times, non-speci¢c association of liposomes
and leakage may contribute to the cytotoxicity of
non-targeted liposomes. MAb contributed little to
the cytotoxicity; free anti-CD19 had an IC50 of
greater than 1.28 WM (Table 2). In comparison, at
the IC50 for DXR-SIL[anti-CD19] of 9.97 WM, the
amount of coupled anti-CD19 was equivalent to a
mAb concentration of 10 nM. Empty SIL[anti-
CD19] (no drug), at comparable antibody densities,
showed low cytotoxicity to ARH77 cells (Table 2).
To determine whether the free anti-CD19 sensitizes
cells to DXR, we co-incubated cells with 3.2U1037
Fig. 4. Internalization of liposomal HPTS by ARH77 cells.
Liposomes 109 nm in diameter were composed of
HSPC:CHOL:Hz-PEG2000-DSPE:mAb anti-CD19 or
PC40:CHOL:Hz-PEG2000-DSPE: mAb anti-CD19, both at a
2:1:0.1:0.002 molar ratio (50 Wg anti-CD19/Wmol PL) and con-
taining encapsulated HPTS. ARH77 cells were exposed to either
HPTS-SL (empty bars), HPTS-HSPC-SIL[anti-CD19] (solid
bars) or HPTS-PC40-SIL[anti-CD19] (hatched bars) under the
following treatment conditions: (A) 1 h, 4‡C; (B) 1 h, 37‡C;
(C) 24 h, 37‡C; or (D) sodium azide-treated ARH77 for 1 h at
37‡C. The pH environment of the liposomes inside cells was de-
termined from the ratio of the excitation peaks, 403/413 to 450/
413 nm (n = 3). *Student’s t-test, P6 0.01.
Table 2
Cytotoxicity of various liposomal formulations, free drug or free anti-CD19
Treatmenta IC50, 1 h IC50, 24 h
Drug-free SIL[anti-CD19] (PL) s 1500 580
Free DXR (DXR) 1.28 þ 0.16 0.47 þ 0.03
DXR-HSPC-SL (DXR) 265.8 þ 32.0 10.4 þ 0.6
DXR-HSPC-NSIL[IgG2a] (DXR) 165.8 þ 17.2 7.9 þ 2.2
DXR-HSPC-SIL[anti-CD19] (DXR) 9.97 þ 2.3 0.98 þ 0.02
DXR-PC40-SL (DXR) 2.75 þ 0.30 0.33 þ 0.06
DXR-PC40-SIL[anti-CD19] (DXR) 1.06 þ 0.29 0.16 þ 0.05
Free anti-CD19 (mAb) s 1.28 s 1.28
Free IgG2a isotype match (mAb) s 1.28 s 1.28
Anti-CD19+free DXR (DXR) 1.06 þ 0.40 0.09 þ 0.02
Anti-CD19+DXR-HSPC-SL (DXR) 245.0 þ 59.8 75.6 þ 37.8
Anti-CD19+DXR-HSPC-SIL[anti-CD19] (DXR) 235.2 þ 32.4 23.7 þ 2.7
IC50 ratio, DXR-HSPC-SL:DXR-HSPC-SIL[anti-CD19] 26.7:1 10.6:1
IC50 ratio, DXR-PC40-SL:DXR-PC40-SIL[anti-CD19] 2.6:1 2.1:1
IC50 ratio, anti-CD19+DXR-SL:anti-CD19+DXR-SIL[anti-CD19] 1.1:1 3.2:1
ARH77 cells (5U105/well) were incubated with various treatments for 1 or 24 h, after which cells were washed and placed in wells
containing fresh media. At 48 h, MTT solution (25 Wg/well) was added to each well and the plates were further incubated for 4 h at
37‡C. The colored formazan product was dissolved using 100 Wl of acid-isopropanol and the plates were read on a Titertek Multiskan
Plus (Flow Laboratories, Mississauga, Ont., Canada) at dual wavelengths 570 and 650 nm. Means þ S.D., n = 3.
aNotation in brackets indicates whether the IC50 is for DXR, PL or Ab.
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Wmol of free anti-CD19 in addition to either free
DXR or liposomal DXR in order to saturate all
CD19 sites on ARH77 cells (Table 2). Free anti-
CD19 and non-speci¢c IgG2a were not cytotoxic in
the concentration range tested (Table 2). Comparing
the IC50 after 1-h incubations, there was no di¡er-
ence between the cytotoxicities of either free DXR or
free DXR combined with anti-CD19 (Ps 0.05). The
cytotoxicity of DXR-SL plus anti-CD19 was com-
parable to that of DXR-SL alone (Ps 0.05) (Table
2). The combination of free anti-CD19 with DXR-
SIL[anti-CD19] increased the IC50 of the liposomes
by 24-fold (P6 0.001), similar to that of non-tar-
geted DXR-SL (Ps 0.05). This indicates that free
anti-CD19 competitively inhibited the binding of
DXR-SIL[anti-CD19] to ARH77 cells.
3.4. Interactions of immunoliposomes with PBMC
from MM patients
We used two-color immuno£uorescence and £ow
cytometry to determine whether SIL[anti-CD19] spe-
ci¢cally bound B cells in heterogeneous populations
of PBMC from MM patients (Fig. 5). NBD-PE-con-
taining liposomes were incubated with PBMC; indi-
vidual populations of B and T cells were identi¢ed by
staining with anti-CD20-PhE or anti-CD4,8-PhE, re-
spectively. B cells were stained with anti-CD20-PhE
instead of anti-CD19-PhE because competition exists
between binding of SIL[anti-CD19] and free anti-
CD19 (see Fig. 2c). Fig. 5 shows a representative
example of PBMC from one patient; it contained
9% B cells and 63% T cells. NBD-SL (Fig. 5A,B),
or NBD-NSIL[IgG2a] (not shown), showed low
binding to MM PBMC, with only 1% of B cells
positive for both NBD-SL and anti-CD20 and only
2% of T cells labelled by both NBD-SL and anti-
CD4,8 (Fig. 5A,B). In contrast, NBD-SIL[anti-
CD19] selectively bound to B cells (7% of PBMC
cells were dual-labelled, Fig. 5D, which corresponds
to 78% speci¢c labelling of B cells). In this patient’s
sample, 63% of the cells stained with CD4,8-PhE
(Fig. 5C) but not NBD-SIL[anti-CD19] (Fig. 5C).
A summary of the results for 10 patients is presented
in Table 3. With the exception of one patient with
20% B cells, all patients had from 5^10% B cells in
their PBMC. SIL[anti-CD19] speci¢cally stained a
larger proportion of B cells than T cells (72% versus
5.3%, respectively, P6 0.001). Binding to B cells of
SIL[anti-CD19] was signi¢cantly higher than binding
of either SL (8.3%, P6 0.001) or NSIL[IgG2a]
(6.7%, P6 0.001), but SL and NSIL[IgG2a] were
not signi¢cantly di¡erent from each other.
Targeting and intracellular distribution of liposo-
mal DXR in PBMC from MM patients were con-
¢rmed using confocal microscopy (Fig. 6). PBMC
were incubated in vitro with liposomal DXR for 1 h
at 37‡C. Individual B and T cells were identi¢ed us-
ing anti-CD19-FITC for B cells and anti-CD4,8 to
detect T cells. Free DXR rapidly stained the nuclei of
both T cells (Fig. 6A) and B cells (Fig. 6B). Neither
DXR-SL (Fig. 6C,D) nor DXR-NSIL[IgG2a] (not
shown) showed an accumulation of DXR into either
T (Fig. 6C) or B cells (Fig. 6D). The cell surface can
be seen in the green channel, but there is little or no
corresponding £uorescence for DXR in the red chan-
nel. DXR-SIL[anti-CD19] incubated with PBMC did
not associate with T cells (Fig. 6E, green channel),
Fig. 5. Two-color £ow cytometry of the binding of immunoli-
posomes by PBMC from a representative MM patient. Lipo-
somes 107 nm in diameter were composed of HSPC:CHOL:
PEG2000-DSPE:NBD-PE (2:1:0.1:0.02 molar ratio) þ mAb anti-
CD19. PBMC from a MM patient were incubated with either
NBD-SIL[anti-CD19] or NBD-SL, then stained with either anti-
CD20-PhE for B cells or anti-CD4,8-PhE for T cells. Dot plots
illustrate the intensity of the two stains on cells treated with:
(A) NBD-SL and anti-CD4,8-PhE; (B) NBD-SL and anti-
CD20-PhE; (C) NBD-SIL[anti-CD19] and anti-CD4,8-PhE; or
(D) NBD-SIL[anti-CD19] and anti-CD20-PhE.
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but did associate with a population of non-T cells
(Fig. 6E, red channel). Lack of co-localization of
the green staining (T cell marker, anti-CD4,8-
FITC) with the red staining (B cell marker, DXR-
SIL[anti-CD19]) suggests that the T cell marker
stained di¡erent cells than the immunoliposomes.
When PBMC were stained with anti-CD19-FITC,
DXR-SIL[anti-CD19] was found to co-localize with
anti-CD19-FITC, con¢rming speci¢city for B cells
(Fig. 6F, green versus red channels). Red punctate
£uorescence within the cytoplasm of MM B cells
suggests that internalization of DXR-SIL[anti-
CD19] occurred (Fig. 6E,F, red channel).
The cytotoxicity of free DXR or liposomal DXR
against PBMC from MM patients was evaluated by
using two-color immuno£uorescence and DAPI
staining for DNA content. Crbc were used as an
internal control to identify the position of diploid
cells. Untreated PBMC from MM patients contained
an average of 11 and 24% apoptotic T and B cells,
respectively (Table 4). (Apoptotic cells are de¢ned as
those having a hypodiploid DNA content, i.e. show-
ing more DAPI staining events in the hypodiploid
(H) and apoptotic (A) regions, but fewer in the dip-
loid and hyperdiploid regions [13].) A representative
example from a single patient is shown in Fig. 7. T
cells had a DNA content approximately three times
that of the Crbc controls (as expected for diploid (D)
cells), while B cells had increased DAPI staining in
the hyperdiploid (4N) region (Fig. 7(1)). Fig. 7(2)
shows that free DXR (5 WM) resulted in the death
of both B and T cell populations, as is evidenced by
increased staining in the H and A regions combined
with decreased staining in the D and 4N regions
(Fig. 7(2)). DXR-SL displayed minimal cytotoxicity
to either B or T cells (Fig. 7(3)). In comparison,
DXR-SIL[anti-CD19] were not cytotoxic to T cells,
but did result in increased apoptosis to B cells (Fig.
7(4) versus (1)).
A summary of the results for 8 MM patient sam-
ples is presented in Table 4. In all patient samples,
free DXR (5 WM) was equally cytotoxic to both B
and T cell populations (Ps 0.05). DXR-SIL[anti-
CD19] was selectively apoptotic to B cells, with low
cytotoxicity to T cells (P6 0.001); B cell cytotoxicity
for the targeted liposomes was not signi¢cantly dif-
Table 3
Speci¢c binding of liposomes to either B or T cells in heterogeneous mixtures of PBMC from MM patients
Liposome formulation % CD20 B cells that bind liposomes % CD4,8 T cells that bind liposomes
SL (n = 10) 8.3 þ 5.3 2.6 þ 4.2
NSIL[IgG2a] (n = 3) 6.7 þ 1.8 1.1 þ 0.3
SIL[anti-CD19] (n = 10) 72.0 þ 20.5 5.3 þ 4.7
PBMC from MM patients were puri¢ed using Ficoll gradients. The percentage of B and T cells in PBMC isolated from each MM pa-
tient blood sample was determined by immuno£uorescent staining with anti-CD19-FITC or anti-CD4,8-PhE, followed by two-color
£ow cytometric analysis. B and T lymphocytes in PBMC from MM patients ranged from 4^20 and 25^70%, respectively (n = 10).
PBMC were incubated with a liposome concentration of 400 nmol PL/ml. Liposome composition was HSPC:CHOL:Hz-PEG-
DSPE:NBD-PE (2:1:0.1:0.02 molar ratio, 100^112 nm in diameter), with or without anti-CD19 or non-speci¢c IgG2a. Speci¢c label-
ling of individual cell populations by liposomes was determined by identi¢cation of cells with anti-CD20-PhE for B cells or anti-
CD4,8-PhE for T cells (see Fig. 5). Means þ S.D.
Table 4
Cytotoxicity of free DXR or various formulations of liposomal
DXR to PBMC from MM patients
Treatment Percent apoptotic cells
B cells T cells
Untreated 24 þ 8 11 þ 6
Free DXR 85 þ 22 73 þ 19
DXR-SL 27 þ 11 13 þ 7
DXR-NSIL[IgG2a] 10 þ 3 5 þ 1.3
Empty SIL[anti-CD19] 21 18
DXR-SIL[anti-CD19] 62 þ 18 17 þ 9
Data represent single measurements or means of 2^4 replicates
for an individual patient sample. PBMC from 8 MM patients
were untreated or treated with free DXR or various liposomal
DXR formulations (5 WM DXR). After incubation, cells were
stained with anti-CD19-FITC, anti-CD4,8-PhE, and DAPI.
Files were gated for either B (CD19) or T (CD4,8) cells ;
their DAPI pro¢les were plotted as DNA histograms (Fig. 7).
The relative DNA content of cells was determined from the po-
sition of the diploid (2N) DNA peak of B and T cells, against
a Crbc internal standard (Fig. 7A). Hypodiploid cells were de-
¢ned as those having 6 2N DNA (determined from their re-
duced DAPI binding). Means þ S.D.
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ferent from that of free DXR (Table 4). DXR-SI-
L[anti-CD19] treatment signi¢cantly increased the
percentage of apoptotic B cells compared with
DXR-SL, NSIL[IgG2a] or untreated controls
(P6 0.001, Table 4). Empty SIL[anti-CD19] were
not cytotoxic at mAb and lipid doses were equivalent
to those used for immunoliposomal DXR (Table 4).
4. Discussion
Our previous study on the use of immunoliposo-
mal DXR to treat human B lymphoma suggested
that this treatment may be applicable to other B
cell malignancies, including MM [32]. In MM, large
numbers of malignant B cells are present in blood
and bone marrow [4,6,7]. This makes MM amenable
to treatment with targeted immunoliposomal drugs,
particularly sterically stabilized formulations that re-
main in the blood for prolonged times [51]. The work
reported here demonstrates that DXR-SIL[anti-
CD19] is selectively targeted to the human CD19
MM cell line ARH77 and to CD19 clonotypic B
cells in PBMC from MM patients.
It has been previously shown that mAb anti-CD19
binds CD19 with a high a⁄nity [18,36], whereas cou-
Fig. 6. Interaction of immunoliposomal DXR with PBMC from MM patients, as visualized using confocal microscopy. Liposomes
were composed of HSPC:CHOL:Hz-PEG2000-DSPE, 2:1:0.1 molar ratio (108 nm in diameter) þ mAb anti-CD19 or irrelevant mAb
IgG2a and contained encapsulated DXR. PBMC from MM patients (2U106 cells) were incubated with either free DXR or various
liposomal formulations of DXR at 20 Wg DXR/ml for 1 h at 37‡C. After incubation with liposomes, cells were washed and stained
with anti-CD19-FITC or anti-CD4,8-FITC. Green channel, antibody (FITC) £uorescence; red channel, DXR £uorescence. (A) Free
DXR and anti-CD4,8-FITC; (B) free DXR and anti-CD19-FITC; (C) DXR-SL and anti-CD4,8-FITC; (D) DXR-SL and anti-CD19-
FITC; (E) DXR-SIL[anti-CD19] and anti-CD4,8-FITC; and (F) DXR-SIL[anti-CD19] and anti-CD19-FITC.
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pling of anti-CD19 on SIL retains the a⁄nity of the
free antibody [32]. The binding studies with ARH77
show that, compared with non-targeted liposomes,
SIL[anti-CD19] rapidly and speci¢cally associates
with cells, even though the ARH77 cells express rel-
atively low levels of CD19 binding sites. The relative
KD of the anti-CD19 mAb coupled to SIL was cal-
culated as 2.2U1033 WM, which is similar to that
previously reported for a human B cell lymphoma
cell line (1.8U1033 WM) [32]. At maximal binding,
approximately 5300 SIL[anti-CD19] or 1600 SL were
bound per ARH77 cell. This translates into approx-
imately 3700 speci¢c SIL[anti-CD19] binding sites
per ARH77 cell. The fact that equilibrium binding
was not completely attained after 1 h at liposome
concentrations of 1600 Wmol PL/ml suggests that
SIL[anti-CD19] bound to CD19 may be continually
endocytosed and that the CD19 receptors recycle to
the cell surface to participate in further binding.
When we compared the cytotoxicity of a leaky
formulation of SIL[anti-CD19] with that of a non-
leaky formulation, we observed higher cytotoxicity
for the leaky formulation (DXR-PC40-SIL[anti-
CD19]). The di¡erence between DXR-PC40-SL and
free drug is marginally signi¢cant at 24 h (P6 0.02).
Free drug is washed away after 1 h incubation, but
the liposomal drug is still present in liposomes bound
non-speci¢cally to the cells. Leakage from the bound
liposomes over 24 h appears to result in higher DXR
levels in cells, hence the lower cytotoxicity compared
with that of free DXR. This is also indirectly illus-
trated in Fig. 2b, in which PC40 liposomes show a
two-fold higher relative mean £uorescence compared
with HSPC liposomes, indicating higher non-speci¢c
absorption. Cytotoxicities of DXR-PC40-SIL and
free drug are signi¢cantly di¡erent (P6 0.008).
DXR-PC40-SL and DXR-PC40-SIL both contained
a low phase transition PL, PC40 [51].
Fig. 7. In vitro cytotoxicity of free DXR and various liposomal DXR formulations from a MM patient PBMC (5 WM DXR concen-
tration for all formulations). Gated populations of B (solid line) or T cells (dotted line) were selected by appropriate staining with ei-
ther anti-CD19-FITC (B cells) or anti-CD4,8-PhE (T cells) ; each population was analyzed independently for its DAPI content. Histo-
gram panels (1)^(4) illustrate DAPI pro¢les of PBMC from a single patient: (1) untreated B or T cells and internal Crbc control
(dashed line); (2) free DXR; (3) non-targeted DXR-SL; and (4) DXR-SIL[anti-CD19].
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Studies using free anti-CD19 to target B cell tu-
mors have suggested that anti-CD19 signals a series
of intracellular messages that lead to B cell di¡er-
entiation, cell arrest or apoptosis [21,49,52]. We
were unable to observe any e¡ect of free anti-CD19
in our in vitro cytotoxicity assays using concentra-
tions of up to 1 WM. In the cytotoxicity studies re-
ported here, anti-CD19 did not induce any increased
sensitivity of ARH77 cells to free DXR or liposomal
DXR. In fact, at 1 h, free anti-CD19 in conjunction
with targeted DXR-SIL[anti-CD19] competitively in-
hibited the action of DXR-SIL[anti-CD19], produc-
ing an IC50 equivalent to that of non-targeted lipo-
somes. Although both anti-CD19 and DXR-
SIL[anti-CD19] compete for the same membrane re-
ceptor, they may subsequently have cytotoxic e¡ects
via independent pathways, i.e. anti-CD19 signalling
of apoptosis [21,49,52^54] versus DXR-induced
DNA strand breaks in cells [55].
In myeloma PBMC, the exposure of cells to free
DXR resulted in a non-selective cytotoxicity to both
the B and T cell populations. However, immunolipo-
somal DXR was selectively cytotoxic to a large frac-
tion of the B cells in MM blood, while leaving the T
cells relatively una¡ected (Fig. 7, Table 4). The abil-
ity of immunoliposomal DXR to selectively eradicate
the circulating malignant B cell clone in vitro may
have use in the treatment of MM in vivo. In this
case, the pharmacokinetics of the liposomal drug car-
rier relative to the free drug may be advantageous.
The rapid redistribution of free DXR (t1=26 5 min)
following intravenous administration in humans
leads to low plasma drug levels and hence to low
cytotoxicity. Encapsulation of DXR in SL maintains
steady DXR levels for several hours in circulation;
the t1=2 is approximately 48 h in humans [56]. We
have previously shown in mice that the t1=2 for SIL
is similar to that for SL, suggesting that the SIL
should have su⁄cient circulation times in humans
to allow the liposomes to speci¢cally bind to, and
be taken up by, tumor cells.
P-gp associated with multidrug resistance is widely
expressed in the B cells of MM patients [5,12,13].
Drugs like DXR, which are substrates for P-gp, are
actively transported from P-gp-expressing cells, lead-
ing to low intracellular drug levels [5,57^59]. Our
data show that the interaction of B cells with tar-
geted DXR-SIL[anti-CD19] results in perinuclear,
punctate DXR £uorescence throughout the cyto-
plasm. These observations are consistent with rapid
cellular uptake of DXR-SIL[anti-CD19] by receptor-
mediated endocytosis into endosomes [60^62]. Rout-
ing of a drug through receptor-mediated endocytosis
may bypass the P-gp transporter, allowing eventual
delivery of the drug to the nucleus [62], possibly ex-
plaining why the immunoliposomal DXR was e¡ec-
tive against P-gp-expressing MM cells.
MM still remains largely incurable. Combination
chemotherapy, radiotherapy and bone marrow trans-
plants have resulted in limited therapeutic success
[1,3,63]. Although these therapies are able to elimi-
nate the plasma cells from the bone marrow, CD19
malignant B cells in the blood still persist after treat-
ment and presumably have regenerative potential [4^
6]. Relapse has been suggested to occur as these
blood B cells continuously di¡erentiate into end-
stage plasma cells that migrate to the bone marrow
[7,8]. Treatment with DXR-SIL[anti-CD19] may
eradicate the malignant clone of circulating B cells,
preventing these cells from repopulating the bone
marrow and hence decreasing the likelihood of re-
lapse. Although this treatment will also target nor-
mal B cells, in relapsed MM patients the vast major-
ity of circulating B cells is derived from malignant
clones. Presumably, normal B cells could be repopu-
lated from end-stage plasma cells that do not express
(or express low levels) of CD19 and would thus sur-
vive the immunoliposomal treatment.
This strategy is dependent on the extent to which
the malignant B cells maintain surface expression of
CD19 or other suitable target epitopes. Shedding or
down-regulation of epitopes would limit this ap-
proach [17,20,29,52,64]. Highly expressed, stable, in-
ternalizing antigens like CD19 appear to be ideal
target epitopes for such antibody-based therapies
[17,19,52]. An attractive approach could be the use
of a combination of several di¡erent immunolipo-
somes (including CD19 [26], CD20 [65], CD22 [66]
and/or CD38) that would target both the malignant
blood B cells and plasma cell components of this
disease.
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